Tamoxifen (Hormone Therapy)
Treatment for Breast Cancer
Typical Dosage: 20 mg daily
Effectiveness
70%
Safety Score
60%
Clinical Trials
251
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
20 mg daily
Time to Effect
Months to years (for recurrence prevention)
Treatment Duration
5-10 years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$300
Total Annual:$900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$5,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$1,800
Cost per Remission
$4,500
Tamoxifen (Hormone Therapy) Outcomes
for Breast Cancer
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+50%
Remission Rate
+20%
Common Side Effects
Hot flashes
+80%
Nausea
+25%
Vaginal discharge/dryness
+20%
Endometrial cancer
+0.2%
Deep vein thrombosis
+1%
Active Clinical Trials
8 active trials recruiting for Tamoxifen (Hormone Therapy) in Breast Cancer
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT06507618RECRUITINGPHASE3
354 participants
INTERVENTIONAL
Charlottesville, United States +2 more
Started: Jul 19, 2024
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
NCT02764541ACTIVE NOT RECRUITINGPHASE2
195 participants
INTERVENTIONAL
Stamford, United States +10 more
Started: May 24, 2016
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
NCT04476485RECRUITING
1K participants
OBSERVATIONAL
Harbin, China +11 more
Started: Jul 19, 2021
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
NCT04740697RECRUITINGNA
200 participants
INTERVENTIONAL
Toulouse, France
Started: Feb 12, 2021
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
NCT03917082ACTIVE NOT RECRUITINGPHASE2
290 participants
INTERVENTIONAL
Vancouver, Canada
Started: Sep 23, 2019
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01272037ACTIVE NOT RECRUITINGPHASE3
5.02K participants
INTERVENTIONAL
Anniston, United States +1571 more
Started: Jan 15, 2011
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054RECRUITINGPHASE3
8K participants
INTERVENTIONAL
Daphne, United States +673 more
Started: Oct 4, 2022
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
NCT04272801ACTIVE NOT RECRUITINGPHASE2
84 participants
INTERVENTIONAL
Charlottesville, United States +1 more
Started: Apr 7, 2020
Completed Clinical Trials
5 completed trials for Tamoxifen (Hormone Therapy) in Breast Cancer
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
NCT00240071COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Birmingham, United States
Started: Oct 1, 2005
Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
NCT02806544COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Started: Jan 1, 2013
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
NCT00034125COMPLETEDPHASE3
INTERVENTIONAL
Miami, United States +10 more
Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)
NCT03948568COMPLETEDPHASE4
262 participants
INTERVENTIONAL
Ottawa, Canada
Started: Sep 17, 2019
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
NCT03969121COMPLETEDPHASE3
141 participants
INTERVENTIONAL
Clayton, Australia +24 more
Started: Jul 16, 2019
Showing 20 of 251 total trials